Evidence map›Paper›PMID 39254229›Full record

SynthesisHealth technology assessment (Winchester, England)2024

Artificial intelligence software for analysing chest X-ray images to identify suspected lung cancer: an evidence synthesis early value assessment.

Jill Colquitt, Mary Jordan, Rachel Court, Emma Loveman, Janette Parr, Iman Ghosh, Peter Auguste, Mubarak Patel, Chris Stinton

Abstract readSystematic Review
In one paragraph

Synthesis in Health technology assessment (Winchester, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jill ColquittEffective Evidence, Waterlooville, UK.ORCID 0000-0001-5962-2689
Mary JordanWarwick Medical School, University of Warwick, Coventry, UK.ORCID 0000-0002-0497-8634
Rachel CourtWarwick Medical School, University of Warwick, Coventry, UK.ORCID 0000-0002-4567-2586
Emma LovemanWarwick Medical School, University of Warwick, Coventry, UK.ORCID 0000-0001-8226-2634
Janette ParrWarwick Medical School, University of Warwick, Coventry, UK.ORCID 0000-0002-0629-1596
Iman GhoshWarwick Medical School, University of Warwick, Coventry, UK.ORCID 0000-0002-7073-7468
Peter AugusteWarwick Medical School, University of Warwick, Coventry, UK.ORCID 0000-0001-5143-3218
Mubarak PatelWarwick Medical School, University of Warwick, Coventry, UK.ORCID 0000-0001-7573-1447
Chris StintonWarwick Medical School, University of Warwick, Coventry, UK.ORCID 0000-0001-9054-1940

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Lung cancer is one of the most common types of cancer in the United Kingdom. It is often diagnosed late. The 5-year survival rate for lung cancer is below 10%. Early diagnosis may improve survival. Software that has an artificial intelligence-developed algorithm might be useful in assisting with the identification of suspected lung cancer. Objectives: This review sought to identify evidence on adjunct artificial intelligence software for analysing chest X-rays for suspected lung cancer, and to develop a conceptual cost-effectiveness model to inform discussion of what would be required to develop a fully executable cost-effectiveness model for future economic evaluation. Data sources: The data sources were MEDLINE All, EMBASE, Cochrane Database of Systematic Reviews, Cochrane CENTRAL, Epistemonikos, ACM Digital Library, World Health Organization International Clinical Trials Registry Platform, clinical experts, Tufts Cost-Effectiveness Analysis Registry, company submissions and clinical experts. Searches were conducted from 25 November 2022 to 18 January 2023. Methods: Rapid evidence synthesis methods were employed. Data from companies were scrutinised. The eligibility criteria were (1) primary care populations referred for chest X-ray due to symptoms suggestive of lung cancer or reasons unrelated to lung cancer; (2) study designs that compared radiology specialist assessing chest X-ray with adjunct artificial intelligence software versus radiology specialists alone and (3) outcomes relating to test accuracy, practical implications of using artificial intelligence software and patient-related outcomes. A conceptual decision-analytic model was developed to inform a potential full cost-effectiveness evaluation of adjunct artificial intelligence software for analysing chest X-ray images to identify suspected lung cancer. Results: None of the studies identified in the searches or submitted by the companies met the inclusion criteria of the review. Contextual information from six studies that did not meet the inclusion criteria provided some evidence that sensitivity for lung cancer detection (but not nodule detection) might be higher when chest X-rays are interpreted by radiology specialists in combination with artificial intelligence software than when they are interpreted by radiology specialists alone. No significant differences were observed for specificity, positive predictive value or number of cancers detected. None of the six studies provided evidence on the clinical effectiveness of adjunct artificial intelligence software. The conceptual model highlighted a paucity of input data along the course of the diagnostic pathway and identified key assumptions required for evidence linkage. Limitations: This review employed rapid evidence synthesis methods. This included only one reviewer conducting all elements of the review, and targeted searches that were conducted in English only. No eligible studies were identified. Conclusions: There is currently no evidence applicable to this review on the use of adjunct artificial intelligence software for the detection of suspected lung cancer on chest X-ray in either people referred from primary care with symptoms of lung cancer or people referred from primary care for other reasons. Future work: Future research is required to understand the accuracy of adjunct artificial intelligence software to detect lung nodules and cancers, as well as its impact on clinical decision-making and patient outcomes. Research generating key input parameters for the conceptual model will enable refinement of the model structure, and conversion to a full working model, to analyse the cost-effectiveness of artificial intelligence software for this indication. Study registration: This study is registered as PROSPERO CRD42023384164. Funding: This award was funded by the National Institute for Health and Care Research (NIHR) Evidence Synthesis programme (NIHR award ref: NIHR135755) and is published in full in

Indexed as

Artificial IntelligenceCost-Benefit AnalysisLung NeoplasmsSoftwareTechnology Assessment, BiomedicalAlgorithmsEarly Detection of CancerHumansRadiography, ThoracicSensitivity and SpecificityUnited KingdomARTIFICIAL INTELLIGENCEECONOMICLUNG NEOPLASMSMODELSRADIOGRAPHYREVIEWTHORACICX-RAYS

Identifiers

PMID39254229
PMCPMC11403378

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.